USP and Public Policy
Left
Refine Your Search
USP appreciates the opportunity to comment on the Food and Drug Administration’s (FDA) draft guidance, “Nonproprietary Naming of Biological Products: Update.”
Learn More
USP appreciates the opportunity to comment on the above referenced FDA Request for Comments on Scientific Data and Information About Products Containing Cannabis or Cannabis-Derived Compounds.
Learn More
USP appreciates the opportunity to provide written comments in addition to the oral testimony USP gave on September 04, 2018, during the public hearing on competition and innovation in the biological…
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration's (FDA) draft guidance: Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management.
Learn More
USP offers thoughts on FDA’s Nutrition Innovation Strategy. USP’s mission aligns closely with that of FDA– ensuring that safe, quality food ingredients are available, along with adequate information…
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration's (FDA) revised draft guidance on " appreciates the opportunity to comment on the Food and Drug Administration…
Learn More
USP appreciates the opportunity to provide comments on the Food and Drug Administration's (FDA) Draft Guidance "ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer…
Learn More
USP appreciates the opportunity to provide written comments in addition to the oral testimony we gave on July 26, 2018, during the public meeting on “FDA’s Comprehensive, Multi-Year Nutrition…
Learn More
USP comments in the SIDI comment form on Standardized Information on Dietary Ingredients (SIDI) Protocol.
Learn More
USP respectfully submits comments on the Food and Drug Administration’s (FDA) Final Guidance, Nonproprietary Naming of Biological Products (Final Guidance).
Learn More